Patents by Inventor Kenji Cunnion
Kenji Cunnion has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240067680Abstract: The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.Type: ApplicationFiled: October 3, 2023Publication date: February 29, 2024Applicant: REALTA HOLDINGS, LLCInventors: Neel K. KRISHNA, Kenji CUNNION
-
Publication number: 20240010681Abstract: The present invention provides peptides that are synthetic modifications of Polar Assonant (PA) peptide including C-terminal PEGylation. The invention further provides methods of using least one synthetic peptide for regulating the complement system and interacting with neutrophils to alter their binding and activity.Type: ApplicationFiled: September 27, 2021Publication date: January 11, 2024Applicant: REALTA LIFE SCIENCES, INC.Inventors: Neel K. KRISHNA, Kenji CUNNION, Ulrich THIENEL
-
Publication number: 20230414506Abstract: The present invention provides synthetic peptides. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to pharmaceutical formulations of the peptides including lipid-based formulations and formulations suitable for intravenous administration.Type: ApplicationFiled: November 3, 2021Publication date: December 28, 2023Applicant: REALTA LIFE SCIENCES, INC.Inventors: Neel K. KRISHNA, Kenji CUNNION
-
Patent number: 11814414Abstract: The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.Type: GrantFiled: February 8, 2021Date of Patent: November 14, 2023Assignee: REALTA HOLDINGS, LLCInventors: Neel K. Krishna, Kenji Cunnion
-
Publication number: 20230321201Abstract: A method of treating systemic lupus erythematosus in a subject is provided in which a therapeutically effective amount of PIC1 is administered to the subject. A method of treating transfusion-related acute lung injury is also provided where a therapeutically effective amount of PIC1 is administered to the subject. PIC1 can modulate immune complex activation of the complement system and NET formation in the subject. PIC1 can also inhibit myeloperoxidase (MPO) activity in the subject.Type: ApplicationFiled: June 9, 2023Publication date: October 12, 2023Applicant: REALTA HOLDINGS, LLCInventors: Neel K. KRISHNA, Kenji Cunnion
-
Publication number: 20230303623Abstract: The present invention provides synthetic peptides. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assonant (PA) peptide, which is a scrambled peptide derived from human astrovirus protein. In some embodiments, the invention is directed to peptides that are modifications of PA including sarcosine substitutions at certain amino acid positions that are stapled and/or have D-enantiomeric substitutions of certain amino acids. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.Type: ApplicationFiled: November 1, 2021Publication date: September 28, 2023Applicant: REALTA LIFE SCIENCES, INC.Inventors: Neel K. KRISHNA, Kenji CUNNION, Ulrich THIENEL
-
Publication number: 20230272012Abstract: The present invention provides synthetic peptides. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human astrovirus protein. In some embodiments, the invention is directed to peptides that are modifications of PA including sarcosine substitutions at certain amino acid positions that are stapled and/or have D-enantiomeric substitutions of certain amino acids. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.Type: ApplicationFiled: November 1, 2021Publication date: August 31, 2023Applicant: REALTA LIFE SCIENCES, INC.Inventors: Neel K. KRISHNA, Kenji CUNNION
-
Patent number: 11712462Abstract: A method of treating systemic lupus erythematosus in a subject is provided in which a therapeutically effective amount of PIC1 is administered to the subject. A method of treating transfusion-related acute lung injury is also provided where a therapeutically effective amount of PIC1 is administered to the subject. PIC1 can modulate immune complex activation of the complement system and NET formation in the subject. PIC1 can also inhibit myeloperoxidase (MPO) activity in the subject.Type: GrantFiled: April 30, 2021Date of Patent: August 1, 2023Assignee: REALTA HOLDINGS, LLCInventors: Neel K. Krishna, Kenji Cunnion
-
Publication number: 20230151058Abstract: The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.Type: ApplicationFiled: August 19, 2022Publication date: May 18, 2023Applicant: REALTA HOLDINGS, LLCInventors: Neel K. KRISHNA, Kenji CUNNION
-
Publication number: 20220249596Abstract: A method of treating hypoxic ischemic encephalopathy (HIE) is described in which a classical complement pathway inhibitor is administered to a neonate. The classical pathway inhibitor can be PIC1, and may have one or more PEG moieties. Treatment of the neonate with the classical complement pathway inhibitor can inhibit inflammation and oxidative damage, such as might arise from ischemia-reperfusion injury. Improvement in fine motor performance, spatial memory and may be achieved. The method may be effective to treat or prevent cerebral palsy.Type: ApplicationFiled: May 28, 2020Publication date: August 11, 2022Applicant: REALTA HOLDINGS, LLCInventors: Neel K. KRISHNA, Kenji CUNNION, Tushar SHAH
-
Publication number: 20220127306Abstract: The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.Type: ApplicationFiled: January 12, 2022Publication date: April 28, 2022Applicant: REALTA HOLDINGS, LLCInventors: Neel K. KRISHNA, Kenji CUNNION
-
Publication number: 20220096592Abstract: A method of improving the lifespan of transfused platelets is described. The method may be useful for patients with alloimmunozation who are refractory to transfused platelets. A method of treating delayed hemolytic transfusion reaction is also described. Also described are PIC1 peptide variants with improved solubility and activity.Type: ApplicationFiled: February 13, 2020Publication date: March 31, 2022Applicant: REALTA HOLDINGS, LLCInventors: Neel K. KRISHNA, Kenji CUNNION
-
Patent number: 11135272Abstract: A method of treating systemic lupus erythematosus in a subject is provided in which a therapeutically effective amount of PIC1 is administered to the subject. A method of treating transfusion-related acute lung injury is also provided where a therapeutically effective amount of PIC1 is administered to the subject. PIC1 can modulate immune complex activation of the complement system and NET formation in the subject. PIC1 can also inhibit myeloperoxidase (MPO) activity in the subject.Type: GrantFiled: January 8, 2019Date of Patent: October 5, 2021Assignee: REALTA HOLDINGS, LLCInventors: Neel K. Krishna, Kenji Cunnion
-
Publication number: 20210292366Abstract: The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.Type: ApplicationFiled: June 3, 2021Publication date: September 23, 2021Applicant: REALTA HOLDINGS, LLCInventors: Neel K. KRISHNA, Kenji CUNNION
-
Publication number: 20210252113Abstract: A method of treating systemic lupus erythematosus in a subject is provided in which a therapeutically effective amount of PIC1 is administered to the subject. A method of treating transfusion-related acute lung injury is also provided where a therapeutically effective amount of PIC1 is administered to the subject. PIC1 can modulate immune complex activation of the complement system and NET formation in the subject. PIC1 can also inhibit myeloperoxidase (MPO) activity in the subject.Type: ApplicationFiled: April 30, 2021Publication date: August 19, 2021Applicant: REALTA HOLDINGS, LLCInventors: Neel K. KRISHNA, Kenji CUNNION
-
Publication number: 20210228695Abstract: Compositions and methods for treating hemolytic anemia are described. A classical complement pathway inhibitor is used to treat hemolytic anemia, for example ceftriaxone-induced complement-mediated hemolysis. A Complement Hemolysis Using Human Erythrocytes (CHUHE) assay is also described where exogenous ceftriaxone is added to a patients serum to show enhanced lysis of the patients erythrocytes in vitro. Ceftriaxone is shown to initiate classical complement pathway-mediated hemolysis by ex vivo reversal with Peptide Inhibitor of Complement C1 (PIC1).Type: ApplicationFiled: June 5, 2019Publication date: July 29, 2021Applicant: REALTA HOLDINGS, LLCInventors: Neel K. KRISHNA, Kenji CUNNION
-
Publication number: 20210163543Abstract: The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.Type: ApplicationFiled: February 8, 2021Publication date: June 3, 2021Applicant: REALTA HOLDINGS, LLCInventors: Neel K. KRISHNA, Kenji CUNNION
-
Patent number: 11020460Abstract: A method of treating systemic lupus erythematosus in a subject is provided in which a therapeutically effective amount of PIC1 is administered to the subject. A method of treating transfusion-related acute lung injury is also provided where a therapeutically effective amount of PIC1 is administered to the subject. PIC1 can modulate immune complex activation of the complement system and NET formation in the subject. PIC1 can also inhibit myeloperoxidase (MPO) activity in the subject.Type: GrantFiled: April 3, 2020Date of Patent: June 1, 2021Assignee: REALTA HOLDINGS, LLCInventors: Neel K. Krishna, Kenji Cunnion
-
Patent number: 10947279Abstract: The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.Type: GrantFiled: May 1, 2019Date of Patent: March 16, 2021Assignee: REALTA HOLDINGS, LLCInventors: Neel K. Krishna, Kenji Cunnion
-
Patent number: 10933116Abstract: The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.Type: GrantFiled: June 24, 2016Date of Patent: March 2, 2021Assignee: REALTA HOLDINGS, LLCInventors: Neel K. Krishna, Kenji Cunnion